Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ARCTURUS THERAPEUTICS HOLDINGS INC. reported revenue of $82M, down 46.1% year over year. Operating margin was -93.0% and net margin -80.2%, on a free-cash-flow margin of -90.8% with capital expenditure at 0.3% of revenue. Every figure is computed directly from ARCT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $82M | -93.0% | -80.2% |
| FY2024 | $152M | -62.8% | -53.1% |
| FY2023 | $167M | -46.9% | -17.8% |
| FY2022 | $206M | 5.9% | 4.5% |
| FY2021 | $12M | -1641.3% | -1648.0% |
How does ARCT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.